![]() | |
Company type | Private |
---|---|
Industry | Science Online marketplace |
Founded | 2007 |
Founders | Kevin Lustig, Chris Petersen, Andrew Martin |
Headquarters | , |
Key people | Kevin Lustig (Founder & CEO) Chris Petersen (Founder & CIO) Daniel Kagan (COO) |
Number of employees | 115 (June 2022) |
Website | scientist |
Scientist.com (formerly known as Assay Depot) is a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services. [1] [2] [3] The company was founded in 2007 by Kevin Lustig, Chris Petersen and Andrew Martin and launched its first public research marketplace in September 2008. [4] [5] [6] [7]
Research marketplaces make it possible for scientists to use contract research organizations (CROs) to outsource an entire pharmaceutical drug discovery project without requiring physical access to a laboratory. [8] [9] [10] [11] [12] The company has been referred to as the “Amazon.com for medical research,” “A Home Depot for science and medicine” and the “EBay for drug discovery services." [2] [7] [13] [14] In 2011 and 2012, Scientist.com launched outsourcing marketplaces for the large pharmaceutical companies Pfizer and AstraZeneca, respectively. [1] [15] [16] [17] [18] [19] The marketplace was featured in a 2012 TEDMED talk given by then-Stanford University professor Atul Butte. [14] [20] In 2013, the company launched a private academic marketplace for the National Cancer Institute. [21] By June 2016, when the company rebranded as Scientist.com, it operated private research marketplaces for 10 pharmaceutical companies and the US National Institutes of Health. [21] [22] In 2017, Scientist.com rolled out a series of new marketplace features to attract more customers, including COMPLi®, a comprehensive process that oversees the sourcing of regulated services for scientific research, such as the legal and ethical acquisition of biological specimens, animal welfare, toxicology studies, secondary real world evidence (RWE), health economics and outcomes research (HEOR), and GxP services. [23] [24] [25] By the end of 2017, the company operated private marketplaces for most of the world's major pharmaceutical companies and entered into a collaboration with VWR International to create an end-to-end research solution. [26] In 2018, Scientist.com launched DataSmart, a platform to ensure data integrity; DataSmart is based on proprietary blockchain technology developed by Scientist.com. [27] [28] [29] The company also opened an office in Tokyo, Japan in 2018 in order to work more closely with Japanese pharma companies. [30] [31] In 2019, Scientist.com unveiled its first original service offering, Trial Insights, a digital reporting platform that aggregates publicly available clinical trials data into usable online dashboards. [32] Later in 2019, Scientist.com launched SciPay, an early-payment program for the thousands of registered suppliers on its marketplace. [33] In late 2020, Scientist.com acquired HealthEconomics.Com, the world’s leading ConnectedCommunity in the Value, Evidence and Access space. [34] Then, in 2021, Scientist.com completed three additional acquisitions, one of which was InsideScientific, an online environment that facilitates the exchange of scientific information via webinars, podcasts, and more. [35] Next, was Notch8, which provides software and app development services, and have since rebranded as Scientist.com Software Solutions. [36] Lastly, is BioPharmCatalyst, an online resource for stock market investors of publicly traded biotech and pharmaceutical companies listed on U.S. markets (NASDAQ and NYSE). [37]
Scientist.com is a procure-to-pay B2B e-commerce marketplace. Research customers use the marketplace to design, purchase and pay for custom research services and products. Research suppliers, or contract research organizations (CROs), use the marketplace to communicate with customers, submit quotes, receive orders and submit invoices. [1] [8] [38] Scientist.com receives a transaction fee on all marketplace purchases.
In spring of 2020, during the COVID-19 pandemic, Scientist.com created a free online tool called the Covid Collaboration Center. [39] [40] [41] Its goal was to empower researchers, protect healthcare workers and help cure this disease.The website connected COVID-19 researchers and promote collaboration, data-sharingand academic and industry partnerships.
In 2013, Scientist.com partnered with the Rare Genomics Institute to create and run a science challenge called Be HEARD (Helping Empower and Accelerate Research Discoveries). [9] [42] [43] Half a million dollars worth of scientific services, ranging in value from $2,500 to $75,000, were awarded to 26 rare disease researchers. [44] [45] In 2015, the Be HEARD science challenge resulted in over $600,000 in awards to 31 rare disease research programs. [46] In 2017, Scientist.com partnered with Global Genes to sponsor the “RARE Battle of the Brains,” a Shark Tank-style pitch competition between early-stage innovators from biotech and academia. [47]
In 2012, Scientist.com partnered with BioCurious in the Bay Area and Genspace in New York to run open science challenges for citizen and young scientists. [48] [49] In 2018, Scientist.com joined France's Brain and Spine Institute incubator, iPEPS-ICM, to launch a call for early stage biotechs to pitch novel approaches to fighting central nervous systems (CNS) disease. [50]
The company raised $1.8M in October 2007 from family and friends. [5] In June 2011, the company raised $1.7M from Hollywood producer Jack Giarraputo and friends. In March 2014, the company raised $3.4M in financing led by Jean Balgrosky of Bootstrap Ventures. [51] [52] In May 2017, the company raised $24M in an equity financing co-led by Boston-based Leerink Transformation Partners (LTP) and San Francisco and Boston-based 5AM Ventures; new investors included Heritage Provider Network, and existing investors Bootstrap Ventures and Jack Giarraputo also participated. [53] [54]
AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.
A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.
WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.
Christoph Westphal is an American biomedical businessman.
Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.
Collaborative Drug Discovery (CDD) is a software company founded in 2004 as a spin-out of Eli Lilly by Barry Bunin, PhD. CDD utilizes a web-based database solution for managing drug discovery data, primarily through the CDD Vault product which is focused around small molecules and associated bio-assay data. In 2021, CDD launched its first commercial data offering, PharmaKB, formerly BioHarmony, as The Pharma KnowledgeBase, which is centered around pharma company, drug, and disease information for research, business intelligence, and investors.
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Atul J. Butte is a biomedical informatics researcher and biotechnology entrepreneur. He is currently the Priscilla Chan and Mark Zuckerberg Distinguished Professor at the University of California, San Francisco. Since April 2015, Butte has serves as inaugural director of UCSF's Bakar Computational Health Sciences Institute.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
Aurora Biosciences was a biotechnology company founded in 1995 in San Diego to commercialize fluorescence assays based on Roger Y. Tsien's discoveries concerning green fluorescent protein and its uses in basic research - work for which Tsien eventually won the 2008 Nobel Prize in chemistry along with two other chemists.
Kevin Donald Lustig is an American scientist and entrepreneur and founder of three life science companies: the pharmaceutical company Kalypsys in 2001; the online research marketplace Scientist.com in 2007; and the non-profit lab incubator Bio, Tech and Beyond in 2013.
Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
Jane Osbourn, OBE, is a scientist and former chair of the UK BioIndustry Association.